Literature DB >> 12196370

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype.

V Bazan1, M Migliavacca, I Zanna, C Tubiolo, N Grassi, M A Latteri, M La Farina, I Albanese, G Dardanoni, S Salerno, R M Tomasino, R Labianca, N Gebbia, A Russo.   

Abstract

BACKGROUND: K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters. PATIENTS AND METHODS: Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for primary colorectal carcinoma, were prospectively studied for K-ras mutations by PCR/single strand conformation polymorphism sequencing.
RESULTS: Seventy-four of the 160 (46%) primary colorectal carcinomas presented mutations in K-ras: 54% in codon 12, 42% in codon 13 (particularly G-->A transition) and 4% in both. Codon 12 K-ras mutations were associated with mucinous histotype (P <0.01), while codon 13 K-ras mutations were associated with advanced Dukes' stage (P <0.05), lymph-node metastasis (P <0.05) and high S-phase fraction (P <0.05). Multivariate analysis showed that codon 13 K-ras mutations, but not any mutation, were independently related to risk of relapse or death.
CONCLUSIONS: Our results suggest that codon 12 K-ras mutations may have a role in the mucinous differentiation pathway, while codon 13 mutations have biological relevance in terms of colorectal cancer clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196370     DOI: 10.1093/annonc/mdf226

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  71 in total

1.  KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.

Authors:  Marta Herreros-Villanueva; Maximiliano Rodrigo; Manuel Claver; Pilar Muñiz; Enrique Lastra; Carlos García-Girón; Maria Jesus Coma del Corral
Journal:  Mol Biol Rep       Date:  2010-06-20       Impact factor: 2.316

2.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

3.  K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.

Authors:  Yelitza Ruiz-Candelaria; Christine Miranda-Diaz; Robert F Hunter-Mellado
Journal:  Int J Biol Markers       Date:  2013-12-17       Impact factor: 2.659

4.  miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.

Authors:  Chiu-Chun Chang; Chun-Che Lin; Chia-Hung Wang; Chi-Chou Huang; Tao-Wei Ke; Po-Li Wei; Ken-Tu Yeh; Kai-Cheng Hsu; Nan-Yung Hsu; Ya-Wen Cheng
Journal:  Oncol Lett       Date:  2018-03-19       Impact factor: 2.967

5.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

Review 6.  The role of targeted therapy in the treatment of advanced colorectal cancer.

Authors:  Marwan Fakih
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

7.  Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes.

Authors:  Jy-Ming Chiang; Yah-Huei Wu Chou; Shih-Chieh Ma; Jim-Ray Chen
Journal:  Virchows Arch       Date:  2004-09-24       Impact factor: 4.064

8.  Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer.

Authors:  Zuo Yunxia; Cao Jun; Zhu Guanshan; Lu Yachao; Zhou Xueke; Li Jin
Journal:  BMC Med Genet       Date:  2010-02-26       Impact factor: 2.103

9.  Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.

Authors:  Kerry J Williams; A Craig Lockhart
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

10.  Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

Authors:  John L Marshall
Journal:  J Oncol       Date:  2009-12-06       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.